Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05390918 · ClinicalTrials.gov registry record · NA

Targeting Adolescent Insomnia to Lessen Overall Risk of Suicidal Behavior

A NA study of Insomnia and Suicidal Ideation, sponsored by Jeff Bridge.

Recruiting
Registry status
NA
Development phase
235
Enrollment target
1
Study location

NCT05390918: Recruiting NA study of Insomnia and Suicidal Ideation, sponsored by Jeff Bridge.

NCT05390918 is a NA study of Insomnia and Suicidal Ideation that is actively recruiting participants, run by Jeff Bridge. The registered enrollment target is 235 participants, above the 169-participant average among 151 other Insomnia trials with a reported enrollment target (39% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05390918, a NA study of Insomnia and Suicidal Ideation, is actively recruiting participants, sponsored by Jeff Bridge.

RECRUITING
Registry status
NA
Development phase
235 participants
Enrollment target
1
Study location

Study Summary

This study will test the effectiveness of a sleep-related primary suicide prevention program entitled TAILOR (Targeting Adolescent Insomnia to Lessen Overall Risk of Suicidal Behavior), which includes specific behavior-change strategies for adolescents at risk of suicidal behavior who suffer from difficulties falling asleep, staying asleep, and/or insufficient sleep.

Primary Outcome

The ASQ is a validated 4-item screen for suicidal ideation and behavior (yes/no) administered via interview. There is an additional 5th item if there is endorsement of one or more of the previous items.

Interventions

  • OTHER Enhanced Usual Care
  • BEHAVIORAL TAILOR

Study Locations (1)

Ohio

  • Nationwide Children's Hospital - Columbus

Trial Details

FieldValue
Enrollment Target 235 participants
Start Date 2022-10-20
Est. Completion 2027-02
Phase NA
Jeff Bridge

2 total trials

What NCT05390918 shows while recruiting

NCT05390918 is an interventional study that assigns participants to a tested intervention. The registered 235 participants enrollment target is mid-sized for trials with a published cap, above the 169-participant average among 151 other Insomnia trials with a reported enrollment target (39% higher).

The record links to 3 conditions, with Insomnia appearing as the primary indexed condition, and to 2 interventions - of which Enhanced Usual Care is the first listed.

NCT05390918 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT05390918 about?

NCT05390918 is a clinical study titled "Targeting Adolescent Insomnia to Lessen Overall Risk of Suicidal Behavior". This study will test the effectiveness of a sleep-related primary suicide prevention program entitled TAILOR (Targeting Adolescent Insomnia to Lessen Overall Risk of Suicidal Behavior), which includes specific behavior-change strategies for adolescents at risk of suicidal behavior who suffer from di...

What is the current status of trial NCT05390918?

This trial is currently recruiting. It is a NA study. The enrollment target is 235 participants. The study started on 2022-10-20. Estimated completion is 2027-02.

What conditions does trial NCT05390918 study?

This clinical trial studies the following conditions: Insomnia, Suicidal Ideation, Suicide, Attempted.

What interventions are being tested in trial NCT05390918?

The interventions under investigation include: Enhanced Usual Care (OTHER), TAILOR (BEHAVIORAL).

Who is sponsoring clinical trial NCT05390918?

This trial is sponsored by Jeff Bridge, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05390918 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Insomnia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05390918's enrollment target sits among peer trials

235 31st of 151 higher than 121 of 151 other Insomnia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Insomnia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01524211 · 235 participants · NA

    Evaluation of Branch Endografts in the Treatment of Aortic Aneurysms

  • NCT05316155 · 235 participants · Phase 1

    Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

  • NCT05353569 · 235 participants · NA

    Coherent Optical Detection of Middle Ear Disease

  • NCT05540704 · 235 participants · NA

    Study Comparing Acceptance and Commitment Therapy to Supportive Diabetes Counseling and a Waitlist Control for Eating Disorders in Type 1 Diabetes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05390918, the US trial registry maintained by the National Library of Medicine. NCT05390918 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.